Pharvaris Outlines 2026 Strategic Priorities
Pharvaris Outlines 2026 Strategic Priorities GlobeNewswire January 12, 2026 Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026 Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026 Recruitment ongoing in CREAATE, a pivotal study of […]